Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome

What Was Tested

The paper reports a study of Oxytocin and Carbetocin in the context of hyperparathyroidism, published as a randomized controlled trial.

Prader-Willi syndrome (PWS) is a genetic neurodevelopmental disorder of life-threatening hyperphagia, obesity, intellectual deficits, compulsivity, and other behavioral problems.

Recruitment was aided by ongoing work in PWS performed through Eunice Kennedy Shriver National Institute of Child Health and Human Development grant U54 HD083211.

Who Took Part

PubMed indexes the participants as children and teenagers, both men and women.

Eligible patients aged 10-18 years with genetically confirmed PWS were randomized (1:1) to i.n. carbetocin or placebo 3 times daily for 14 days.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Oxytocin study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Oxytocin, giving a reference point.

A time span of 14 days appears in the methods.

Endpoints were assessed using analysis of covariance.

Relationship between primary and secondary endpoints was assessed using Pearson correlation coefficients.

Safety was assessed throughout the study.

What Was Measured

Topics PubMed links to this paper include Endpoint Determination, Hyperphagia, Obesity, Oxytocin, Prader-Willi Syndrome and Surveys and Questionnaires.

The authors tagged it with the keywords Clinical Trials, Neurodevelopment and Neuroscience.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin and Carbetocin in people with hyperparathyroidism over 14 days.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (JCI insight), a journal based in United States.

More context: the Oxytocin compound page and the Carbetocin compound page, Hyperparathyroidism research.